Exclusive agreement in June 2025 to commercialize EXXUA™ (gepirone) extended-release tablets ("EXXUA") is expected to serve as a major growth catalyst; the Company anticipates launching EXXUA in the ...
(1) Synopsys manages the business on a long-term, annual basis, and considers quarterly fluctuations of revenue and profitability as normal elements of our business. Amounts may not foot due to ...
The Company generated record revenue of approximately $12.0 million USD and positive net income and free cash flow for Q1'26 ...
House Majority Whip Tom Emmer (R-Minn.) on Thursday floated changing the structure of the federal government’s fiscal calendar by moving the end-of-year Sept. 30 deadline to prevent the cycle of ...
WILMINGTON, N.C., Aug. 26, 2025 (GLOBE NEWSWIRE) -- nCino, Inc. (NASDAQ: NCNO), the leading provider of intelligent, best-in-class banking solutions, today announced financial results for the second ...
We expect the first quarter to be above the full year revenue guidance midpoint by approximately 100 bps. We expect the second quarter to be below the full year revenue guidance midpoint by ...
ZEFIRO METHANE CORP. (Cboe CA: ZEFI) (FSE: Y6B) (OTCQB: ZEFIF) (the "Company", "Zefiro", or "ZEFI") is pleased to provide an update on its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback